Skip to main content

Table 2 Patients outcomes in patients with or without diaphragm atrophy

From: Diaphragm thickness modifications and associated factors during VA-ECMO for a cardiogenic shock: a cohort study

Variable

Patient outcomes according to three groups of diaphragm thickness evolution (: stable, atrophy, increase) using a ultrasound method

Patient outcomes according to the absence or the presence of diaphragm atrophy using a ultrasound method

Increase, N = 41

Decrease, N = 71

Stable, N = 181

p-value2

Non-atrophy, N = 221

Atrophy, N = 71

p-value3

Deceased before VA-ECMO weaning

1 (25%)

3 (43%)

4 (22%)

0.7

5 (23%)

3 (43%)

0.4

VA-ECMO weaning failure

1 (25%)

4 (57%)

7 (39%)

0.6

8 (36%)

4 (57%)

0.4

VA-ECMO days

5 [3.8, 7]

4 [2, 6]

6.5 [4, 11]

0.2

6 [4, 10]

4 [2, 6]

0.10

Days with mechanical ventilation

4 [2, 5]

8 [7, 20]

5 [1, 11]

0.059

5 [1, 10]

8 [7, 20]

0.029

Ventilator free days at day 60

55 [40, 58]

7 [0, 29]

54 [20, 59]

0.056

54 [20, 59]

7 [0, 29]

0.018

Deceased at day 60

1 (25%)

5 (71%)

4 (22%)

0.063

5 (23%)

5 (71%)

0.030

Deceased at day 7

1 (25%)

3 (43%)

1 (5.6%)

0.059

2 (9.1%)

3 (43%)

0.075

  1. Results are reported for patients according to their diaphragm evolution status at the end of patient follow up. The population was divided in three categories whether the diaphragm thickness presented a 10% decrease, increase or remained stable from baseline to the last assessment. Outcomes are presented after 60 days of follow-up (unless otherwise specified)
  2. 1n (%); Median [interquartile range]
  3. 2Fisher’s exact test; Kruskal–Wallis rank sum test
  4. 3Fisher’s exact test; Wilcoxon rank sum test